Equillium collaborates with Vivtex for oral formulation of autoimmune therapy [Yahoo! Finance]
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
a research and licensing deal to use Vivtex's AI-enabled screening platform to optimise the bioavailability of Equillium's autoimmune therapy, EQ302. The partnership, announced yesterday (16 September), supports EQ302 development as Equillium looks to initiate a Phase I trial in the latter half of 2025. Though the financial specifics of the deal have not been made public, Equillium will have the option to enter into a licensing agreement within which Vivtex could be eligible for royalties and other payments. EQ302 is a peptide which targets interleukins (IL)-15 and IL-21, cytokines active in the pathology of several inflammatory conditions. To maximise bioavailability, Equillium will employ Vivtex's GI-ORIS (gastrointestinal organic robotic interface system) platform, an AI-enabled technology which uses porcine GI tissue for high-throughput screening. It is the derivate of a previously promising precursor, EQ102, which was in a Phase I trial for coeliac disease but was dropped a
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium to Present at the Stifel Virtual Inflammation & Immunology SummitBusiness Wire
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceBusiness Wire
- Equillium, Inc. (NASDAQ: EQ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Equillium GAAP EPS of $0.01 beats by $0.16, revenue of $13.9M beats by $7.57M [Seeking Alpha]Seeking Alpha
EQ
Earnings
- 5/9/24 - Beat
EQ
Analyst Actions
- 8/19/24 - HC Wainwright
EQ
Sec Filings
- 9/17/24 - Form 4
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- EQ's page on the SEC website